However, a post-hoc analysis adds to evidence suggesting that irradiating all metastatic lesions may improve survival in patients receiving immune checkpoint inhibitor monotherapy.
The goal of the study was to compare outcomes in very-high-, high-, and low-risk NCCN groups as well as outcomes of CSCCs stratified by treatment with Mohs and wide local excision.
The findings build on previous research and underscore the need for early diagnosis and aggressive surveillance in this patient population, the authors write.
A large review has found no difference in overall survival with fixed-duration vs ongoing ICI treatment in progression-free non–small cell lung cancer.